MET inhibitors for treatment of advanced hepatocellular carcinoma: A review - Wikidata - awgldk - TriplyDB

MET inhibitors for treatment of advanced hepatocellular carcinoma: A review

MET inhibitors for treatment of advanced hepatocellular carcinoma: A review

http://www.wikidata.org/entity/Q27014423

about

Hepatobiliary Tumors: Update on Diagnosis and Management Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer Integrative meta-analysis identifies microRNA-regulated networks in infantile hemangioma Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma.Platelet-derived growth factor receptor α in hepatocellular carcinoma is a prognostic marker independent of underlying liver cirrhosis Receptor tyrosine kinase mutations in developmental syndromes and cancer: two sides of the same coin Clinical guideline SEOM: hepatocellular carcinoma MicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiation therapy.Cabozantinib in the treatment of hepatocellular carcinoma.The Therapeutic Targeting of HGF/c-Met Signaling in Hepatocellular Carcinoma: Alternative Approaches.Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma.Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review.The efficacy and safety of tivantinib in the treatment of solid tumors: a systematic review and meta-analysis.Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody

P2860

Q26775654-611336E9-1C23-4038-AE7F-2966AEB6F978 Q26779960-86DB7E17-94F3-4739-A45E-A96764EA0646 Q28077270-66072BD2-25E3-4552-AAD1-32D2A3041CCE Q29248288-3A8D6A2E-AD05-4249-89BE-74D4D504C982 Q30368024-4FC0EF9D-2DC6-4AA7-AF80-EE658908CC4E Q33889261-71E77533-0464-4B2E-9C7E-14C1BC2873F1 Q36065321-0EFC8F30-099E-4645-8A7B-2386DD62EB32 Q36400259-95910BEA-9CC7-480C-B1A6-3022C79822CD Q37735617-2895177D-9F8E-4799-AD30-25337BA7652C Q38658285-90428172-9FBE-4BF7-8219-9196CC80799B Q38674137-FD8BE3BF-131B-4D95-8765-3F387D042F3A Q38923977-DA99D96C-C8DC-4D6E-B1EF-23015271F4CF Q47139946-8309453B-836D-4F82-BF10-39FDE70C8072 Q47653274-DBCE8138-3956-4145-8DFA-D6B8FF912498 Q48140297-44202F5F-9C69-42B7-80C3-A69F8B815B72 Q58748732-8C4251F5-952B-4CEA-A8A8-63D841F75348

P2860

MET inhibitors for treatment of advanced hepatocellular carcinoma: A review

http://www.wikidata.org/entity/Q27014423

description

2015 nî lūn-bûn

@nan

2015 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

MET inhibitors for treatment of advanced hepatocellular carcinoma: A review

@ast

MET inhibitors for treatment of advanced hepatocellular carcinoma: A review

@en

MET inhibitors for treatment of advanced hepatocellular carcinoma: A review

@nl

type

label

MET inhibitors for treatment of advanced hepatocellular carcinoma: A review

@ast

MET inhibitors for treatment of advanced hepatocellular carcinoma: A review

@en

MET inhibitors for treatment of advanced hepatocellular carcinoma: A review

@nl

prefLabel

MET inhibitors for treatment of advanced hepatocellular carcinoma: A review

@ast

MET inhibitors for treatment of advanced hepatocellular carcinoma: A review

@en

MET inhibitors for treatment of advanced hepatocellular carcinoma: A review

@nl

P1433

Q27014423-D9C42CAD-2857-464E-B277-9F953EB8E938

P1476

Q27014423-0069E131-C6A4-4BEB-A6B7-4278F3C42449

P2093

Q27014423-2C8AEE30-24FB-41A3-85E3-D702177A4C99

Q27014423-68407298-75C4-47CA-BBAA-5621F5C00423

Q27014423-8509E1D8-3174-48D9-BA73-B3741616ADAA

Q27014423-D33CD87B-6C77-459B-8F83-2E800939F6F5

P2860

Q27014423-0D8BE291-E138-4997-95AC-8E957699D7C0

Q27014423-231BA55F-E034-4BD7-AE9E-9B5519598361

Q27014423-27E037B5-9FDD-43F8-8850-5F06D7D81493

Q27014423-3E097F3A-154E-47D3-84AB-6546C90255A3

Q27014423-4A378BA1-FEAF-4A0C-97A5-CEFC65FE682E

Q27014423-58DF7C04-526D-40C6-BED1-4F57A76E734D

Q27014423-607B46C1-0ED0-451D-B7B9-B2A166074C48

Q27014423-60CD314A-DF05-4053-9127-DB281FA8F061

Q27014423-63718AE9-BD31-42C5-AB02-45DB6C487474

Q27014423-67696538-9018-4329-B1EC-55E84B996B93

P304

Q27014423-953B25E8-B5B4-4366-BDC6-B1021E0C74C4

P31

Q27014423-B792448C-6C91-45CF-BDFA-509E358D35C1

P3181

Q27014423-35908085-0F1C-435D-A36F-9556AA0ADB12

P356

Q27014423-23A5CD7D-399B-4E73-B130-A352BBD27763

P407

Q27014423-9CBA6572-37B8-480E-A377-120D923876F5

P433

Q27014423-E015EF3C-DDC7-4CFE-AEE0-14603700C69B

P478

Q27014423-50732F0A-BB81-4F76-A4DC-A54CF4B368F3

P50

Q27014423-C6D583B6-2C7C-433C-84A1-0504535C8D43

P577

Q27014423-363F228B-B460-4489-831E-FFECB9884C51

P5875

Q27014423-4483509F-49BF-49E1-87B0-1BA2E41BB7BE

P698

Q27014423-21F5F473-4094-41E0-B018-C602DBBE6C49

P932

Q27014423-C020D112-BEC2-4F54-B62C-BD6BEFD531DB

P3181

P356

WJG.V21.I18.5445

P1433

World Journal of Gastroenterology

P1476

MET inhibitors for treatment of advanced hepatocellular carcinoma: A review

@en

P2093

Guo-Hong Han

http://www.w3.org/2001/XMLSchema#string

Hong-Yu Li

http://www.w3.org/2001/XMLSchema#string

Jiang Chen

http://www.w3.org/2001/XMLSchema#string

Xiao-Zhong Guo

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Targeting the hepatocyte growth factor-cMET axis in cancer therapy

Management of hepatocellular carcinoma: An update

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

Cancer statistics, 2013

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

Sorafenib in advanced hepatocellular carcinoma

c-Met: structure, functions and potential for therapeutic inhibition

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.

P304

5445-5453

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3387432

http://www.w3.org/2001/XMLSchema#string

P356

10.3748/WJG.V21.I18.5445

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277087185

http://www.w3.org/2001/XMLSchema#string

P698

25987766

http://www.w3.org/2001/XMLSchema#string

P932

4427665

http://www.w3.org/2001/XMLSchema#string